Concord Biotech Launches Injectable Production at New Valthera Facility

Concord Biotech Limited has announced the commencement of production at its new injectable facility in Valthera, near Ahmedabad. This state-of-the-art facility, spread over 94,826 square meters, marks the company's expansion into injectable formulations. The Valthera site, which began operations in 2016 for oral solid dosages, now adds injectable capabilities to its portfolio. This development aligns with Concord's strategy to strengthen its position in the formulation business and diversify its product offerings. The new facility is expected to enhance the company's manufacturing capacity and global market presence, particularly in specialized segments like immunology and oncology.

Sources: Concord Biotech website, BSE filings, CNBC TV18